Floatz logo

cd5/cd7 car-t

T-cell Acute Lymphoblastic Leukemia

Essen BiotechCell therapyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the T-cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Bortezomib
Children's Oncology Group
Phase 2/3BB
Venetoclax
M.D. Anderson Cancer Center
Phase 2B
DARATUMUMAB
Children's Oncology Group
Phase 2/3B
Decitabine
M.D. Anderson Cancer Center
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Children's Oncology Group
Phase 2/3B

View all 20 →

Same molecule, other indications

cd5/cd7 car-t is also rated in:

T Cell LeukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
T-Cell Lymphoma of CNSDormant
CCC
Indicative ·
48 / 100
View asset →
T Cell Prolymphocytic LeukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →